Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity
Cabaletta surges after early data on cell therapy for autoimmune skin disease
Brief: Cabaletta Bio Inc Reports New Data From RESET-PV Trial
Cabaletta Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cabaletta Bio Inc Files For Mixed Shelf Offering Of Up To $240 Million- SEC Filing
Cabaletta Bio Inc expected to post a loss of 65 cents a share - Earnings Preview
Cabaletta Bio Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Cabaletta Bio Announces 2027 Rese-Cel BLA Submission Anticipated In Myositis Following Recent FDA Alignment On Registrational Cohorts
Cabaletta Bio Inc expected to post a loss of 64 cents a share - Earnings Preview
Cabaletta Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Cabaletta Bio Inc expected to post a loss of 64 cents a share - Earnings Preview